

NZX Announcement

2 September 2019

Screening results in Hunan, China exceed expectations


Highlights

- Screening results from 2,065 women across 7 hospitals in Hunan, China exceed expectations
- TruScreen’s cervical cancer screening device demonstrates improved sensitivity and specificity targeting pre-cancerous and cancerous cervical cells
- Conducted by a peak gynaecology body in China, this evidence is a key plank in TruScreen’s commercial platform

Real-time cervical cancer screening technology company TruScreen (NZX:TRU) is pleased to announce that the clinical results of 2,065 women screened for cervical cancer across seven hospitals in Hunan have exceeded expectations.

The China Obstetrics and Gynaecology Association (COGA) is conducting a project that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. Hunan is the first province in China to complete their participation in the project. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China .

COGA Hunan Province interim results showed TruScreen has a Sensitivity of 89.29% (LBC 67.87%, HPV 92.86%) and a Specificity of 87.17% (LBC 90.07%, HPV 84.26%).





Sensitivity and specificity are measures of a test's ability to correctly diagnose disease. A high sensitivity results in fewer false negatives, and a high specificity results in fewer false positives in the screening process.

Publication will occur when the full 20,000 patients have been screened. Interim results from this Hunan clinical evaluation confirm the strong potential for the TruScreen device to improve women's health in China. The Chairperson of COGA Hunan, Professor Xue Ming, presented the results at the Hunan Provincial COGA Annual Congress on Saturday, 24 August 2019 in China.

Results Commentary

TruScreen Chief Executive Martin Dillon said: "We are delighted to be able to report such strong results from the first completed province for the COGA evaluation.

Many hospitals and key opinion leaders have been waiting for such in country evidence to finalise their purchasing and recommendation of our Truscreen devices."

- ENDS -

For more information visit www.TruScreen.com or contact:

TruScreen

Martin Dillon
CEO

martindillon@truscreen.com

TruScreen

Guy Robertson
CFO

guyrobertson@truscreen.com

Investors

Investor Relations

Phone: +61 2 9237 2801

TruScreen@we-buchan.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is middle income countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant. At saturation, hundreds of millions of women could benefit from this accurate and inexpensive cervical cancer screening model.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>